Les nouveaux anticorps dans les neuropathies inflammatoires

Broers, 2019, Incidence and Prevalence of Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-Analysis, Neuroepidemiology, 52, 161, 10.1159/000494291 Lehmann, 2019, Chronic inflammatory demyelinating polyneuropathy: Update on diagnosis, immunopathogenesis and treatment, J Neurol Neurosurg Psychiatry, 90, 981, 10.1136/jnnp-2019-320314 2010, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripher, J Peripher Nerv Syst, 15, 185, 10.1111/j.1529-8027.2010.00278.x Antoine, 2005, Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic strategy. Guidelines of the French CIDP study group, Rev Neurol (Paris), 161, 988 Vallat, 2008, Le microscope électronique. Outil très utile au diagnostic des neuropathies périphériques, Ann Pathol, 28, 486, 10.1016/j.annpat.2008.04.006 Querol, 2013, Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy, Ann Neurol, 73, 370, 10.1002/ana.23794 Ng, 2012, Neurofascin as a target for autoantibodies in peripheral neuropathies, Neurology, 79, 2241, 10.1212/WNL.0b013e31827689ad Appeltshauser, 2020, Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy, Neurol Neuroimmunol neuroinflammation, 7, 1, 10.1212/NXI.0000000000000817 Manso, 2016, Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects, Brain, 139, 1700, 10.1093/brain/aww062 Cortese, 2020, Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype, Neurol Neuroimmunol neuroinflammation, 7, 10.1212/NXI.0000000000000639 Delmont, 2017, Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy, Brain, 140, 1851, 10.1093/brain/awx124 Delmont, 2020, Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera, J Neurol, 267, 3664, 10.1007/s00415-020-10041-z Querol, 2014, Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg, Neurology, 82, 879, 10.1212/WNL.0000000000000205 Devaux, 2016, Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy, Neurology, 86, 800, 10.1212/WNL.0000000000002418 Taieb, 2018, Neuro-renal syndrome? related to anti-contactin-1 antibodies, Muscle Nerve, 59, E19 Doppler, 2016, Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy, Brain, 139, 2617, 10.1093/brain/aww189 Kouton, 2020, Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins, Clin Neurophysiol, 131, 921, 10.1016/j.clinph.2020.01.013 Ogata, 2015, Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy, Ann Clin Transl Neurol, 2, 960, 10.1002/acn3.248 Koike, 2017, Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies, J Neurol Neurosurg Psychiatry, 88, 465, 10.1136/jnnp-2016-314895 Vallat, 2017, Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-neurofascin 155 antibodies, Neuromuscul Disord, 27, 290, 10.1016/j.nmd.2016.10.008 Querol, 2015, Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins, Neurol Neuroimmunol Neuroinflammation, 2, e149, 10.1212/NXI.0000000000000149 Leger, 2015, The pathogenesis of multifocal motor neuropathy and an update on current management options, Ther Adv Neurol Disord, 8, 109, 10.1177/1756285615575269 Ho, 1995, Guillain-Barre-Syndrome in Northern China - Relationship to Campylobacter-Jejuni Infection and Anti-Glycolipid Antibodies, Brain, 118, 597, 10.1093/brain/118.3.597 McGonigal, 2016, C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy, Acta Neuropathol Commun, 4, 23, 10.1186/s40478-016-0291-x Mckhann, 1993, Acute Motor Axonal Neuropathy: A Frequent Cause of Acute Flaccid Paralysis in China, Ann Neurol, 33, 333, 10.1002/ana.410330402 Yuki, 2012, Guillain–Barré Syndrome, N Engl J Med, 366, 2294, 10.1056/NEJMra1114525 Delmont, 2014, Improving the detection of IgM antibodies against glycolipids complexes of GM1 and Galactocerebroside in Multifocal Motor Neuropathy using glycoarray and ELISA assays, J Neuroimmunol, 278, 159, 10.1016/j.jneuroim.2014.11.001 Cats, 2010, Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy, Neurology, 75, 818, 10.1212/WNL.0b013e3181f0738e Azulay, 1994, Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study, Neurology, 44, 429, 10.1212/WNL.44.3_Part_1.429 Léger, 2001, Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study, Brain, 124, 145, 10.1093/brain/124.1.145 Murray, 1984, Indication of a Possible Role in a Demyelinating Neuropathy for an Antigen Shared Between Myelin and Nk Cells, Lancet, 323, 711, 10.1016/S0140-6736(84)92224-4 Kuijf, 2009, Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy, Neurology, 73, 688, 10.1212/WNL.0b013e3181b59a80 Delmont, 2019, Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies, J Neurol, 266, 1973, 10.1007/s00415-019-09367-0 Dalakas, 2018, Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies, Ther Adv Neurol Disord, 11, 1, 10.1177/1756285617746640 Svahn, 2018, Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features, J Neurol Neurosurg Psychiatry, 89, 499, 10.1136/jnnp-2017-316715 Magy, 2015, Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies, J Immunol Res, 450391 Attarian, 2001, Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies, Clin Neurophysiol, 112, 457, 10.1016/S1388-2457(01)00469-2 Vallat, 2021, The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy, Neurology, 96, 214, 10.1212/WNL.0000000000011324 Léger, 2013, Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy, Neurology, 80, 2217, 10.1212/WNL.0b013e318296e92b Lunn, 2016, Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev, 10, CD002827 Aliu, 2020, Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer, J Neurochem, 154, 486, 10.1111/jnc.15021